Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
Initial IV bolus of 80 units/kg, followed by continuous IV infusion at 18 units/kg/hour; subsequent dosing based on aPTT. For DVT/PE: initial bolus of 5,000 units or 80 units/kg, then 1,000-2,000 units/hour continuously.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
30–90 minutes (mean 1.5 h) for therapeutic doses; dose-dependent and saturable elimination: increases with dose (e.g., 100 U/kg: ~56 min; 400 U/kg: ~152 min). At lower doses, half-life may be shorter due to rapid clearance.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Renal: minimal intact heparin; primarily hepatic degradation via desulfation and depolymerization into inactive metabolites (uroheparin) excreted renally. Biliary/fecal: negligible (<1%).
Category C
Category A/B
Anticoagulant
Anticoagulant